P585: Screening newborns for type 1 diabetes risk: The early check experience
Early Check is a voluntary newborn screening (NBS) program available to babies born in North Carolina (NC). Parents can choose to screen their newborns for two panels of monogenic conditions and genetic risk for type 1 diabetes (T1D). T1D is a genetically complex condition that is well positioned for NBS trials because of its high prevalence (1:250), heritability, and existence of surveillance using sequential islet autoantibody testing. An FDA approved treatment, teplizumab, can delay clinical symptoms when implemented in autoantibody positive individuals.
Authors
- Nathan Gaddis (ORCID: https://orcid.org/0000-0001-5205-7138)
- Holly L. Peay (ORCID: https://orcid.org/0000-0002-3053-7453)
- Jennifer Law (ORCID: https://orcid.org/0000-0001-9956-7178)
- Heidi Cope (ORCID: https://orcid.org/0000-0003-0586-9277)
- Katerina S. Kucera (ORCID: https://orcid.org/0000-0003-4148-6599)
- Grier P. Page (ORCID: https://orcid.org/0000-0003-2582-3786)
- Cynthia M. Powell (ORCID: https://orcid.org/0000-0002-4260-5601)
- Jennifer A. Sullivan (ORCID: https://orcid.org/0000-0002-8782-2183)
- Ana Forsythe
- Blythe G. Crissman
- Elizabeth Jalazo
- Angela Gwaltney (ORCID: https://orcid.org/0000-0002-2305-7187)
Institutions
- University of North Carolina at Chapel Hill (US)
- RTI International (US)
Publication Details
- Journal
- Genetics in Medicine Open
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.gimo.2025.102433
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00